Tempest Therapeutics
Focus: Small Molecules for Immuno-Oncology
Tempest Therapeutics is a life sciences company focused on Small Molecules for Immuno-Oncology.
Profile data last refreshed Yesterday
Open Jobs
0
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Part 1 TPST-1120
Hepatocellular CarcinomaClinical Trials (1)
NCT03829436TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Phase 1Help build intelligence for Tempest Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.